Advances in peptidomimetic inhibitors of coronavirus main protease
10.16438/j.0513-4870.2022-0154
- VernacularTitle:拟肽类冠状病毒主蛋白酶抑制剂的研究进展
- Author:
Yu LIU
1
;
Wei MING
1
;
Chen-zong LI
1
;
Yuan-yuan ZHU
2
;
Shuang-xi GU
1
Author Information
1. Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430205, China
2. School of Chemistry and Environmental Engineering, Wuhan Institute of Technology, Wuhan 430205, China
- Publication Type:Research Article
- Keywords:
CoVs;
peptidomimetic inhibitor;
Mpro;
SARS-CoV;
MERS-CoV;
SARS-CoV-2
- From:
Acta Pharmaceutica Sinica
2022;57(7):1977-1990
- CountryChina
- Language:Chinese
-
Abstract:
Coronavirus (CoVs) is a widespread pathogen that can infect humans and animals to cause serious acute and chronic respiratory diseases. Among them, SARS-CoV broke out in 2003, MERS-CoV was discovered and spread widely in 2012, and SARS-CoV-2 emerged at the end of 2019. They all belong to β-coronavirus. Peptidomimetic inhibitors targeting coronavirus main proteases (Mpro, 3CLpro) have attracted much attention because of their broad spectrum and strong antiviral efficacy. In this review, peptidomimetic inhibitors of coronavirus main protease were classified and summarized according to the different "warheads" in design strategy. And also, the molecular structures, biological activity and design ideas of the inhibitors were analyzed and discussed, which is aimed to provide useful reference for further design and development of coronavirus inhibitors.
